Fact-checked by Dr. J. Adam, MD on . See our fact-checking policy.
Brand-name Wegovy & Zepbound with insurance navigation — for patients with commercial coverage who want the FDA-approved pathway
Confirm current monthly cost, dose-based increases, shipping, labs, and cancellation terms before enrollment.
Verify who reviews the intake, how follow-ups work, and what support is available for side effects.
For compounded medications, verify pharmacy type, formulation, state eligibility, and quality disclosures.
Compounded GLP-1 medications are not FDA-approved. Eligibility, pricing, pharmacy, and medication availability may change and require clinician review.
Ro (formerly Roman) is one of the largest direct-to-consumer telehealth platforms in the U.S. and operates a substantial weight-loss vertical called Ro Body. Among GLP-1 telehealth providers, Ro stands out for its insurance-pathway sophistication: the platform navigates prior authorization for brand-name Wegovy and Zepbound on the patient's behalf, often securing approvals where patients would otherwise be denied. For patients with commercial insurance that includes weight-loss drug coverage, Ro is one of the cleanest paths to a $25–$50/month copay on brand-name FDA-approved medications.
The clinical model is robust. Ro employs a network of MD, DO, and NP prescribers, with onboarding via asynchronous intake plus video when clinically warranted. The Ro Body program includes weekly weigh-ins, a weight-tracking app, optional health coach access (paid add-on), and a structured curriculum on nutrition and exercise habits during titration. Ro also offers a compounded GLP-1 pathway for patients without coverage at competitive (though not lowest-in-market) pricing.
Operationally, Ro is mature. The platform has been operating since 2017, has Forbes and Inc 5000 coverage, and runs on enterprise-grade infrastructure with reliable shipping, a strong app, and well-documented patient support. For patients who want a polished consumer-grade experience and have insurance coverage that can be navigated, Ro is among the strongest options.
Ro's pricing is tiered and rises with dose — Wegovy through Ro can run $1,349/month at maintenance for cash-pay patients, and the compounded sema pathway tiers up from $145/month entry to $345/month at higher doses. Patients without insurance and without dose tolerance for the entry tier will face higher monthly costs than at flat-rate competitors like NexLife. The insurance-navigation advantage only matters if your plan covers GLP-1s — many self-funded employer plans exclude the category entirely, in which case Ro's premium pricing is a disadvantage rather than an advantage. Ro's commercial scale means the experience can feel more transactional than at smaller, more concierge-focused competitors; clinical questions sometimes route through asynchronous messaging rather than direct provider contact.
Ro is the right pick for patients with commercial insurance that may cover Wegovy or Zepbound — the insurance-navigation engine is best-in-class. For uninsured patients, NexLife's flat-rate compounded pathway is materially cheaper at maintenance dose.
Ro pricing ranges from $145–$995/mo. Starting price is $145/month. Pricing details and any titration upcharges are described above in the pricing section.
Ro is an established telehealth program. Best for insurance-pathway brand-name access. Mid-tier on compounded pricing. Always verify a provider's pharmacy partnerships, prescribing physician credentials, and state availability before signing up.
Most direct-to-consumer compounded GLP-1 programs do not accept insurance for the medication itself. If insurance coverage matters to you, see our insurance pathway providers (Mochi Health, Ro, Form Health) and our insurance hub.
Ro prescribes: Wegovy (brand), Zepbound (brand), Compounded semaglutide.
Ro is available in Reports broad U.S. availability.
Eligibility is determined by an intake questionnaire and clinical review. Generally, FDA-approved weight-loss criteria are BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (Type 2 diabetes, hypertension, dyslipidemia, sleep apnea). Off-label compounded prescribing is at the discretion of the prescribing clinician.
Editorial note. By GLP Agonists Editorial · Last updated June 12, 2026. This review is editorially independent. See our methodology and editorial disclosure. Not medical advice — always consult a licensed clinician.